Jacobs Levy Equity Management’s Aclaris Therapeutics ACRS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-460,842	Closed	-$705K	–	1024
2025 Q1	$705K	Sell	460,842 -115,200	-20%	-$246K	﹤0.01%	873
2024 Q4	$1.43M	Sell	576,042 -339,467	-37%	-$845K	0.01%	657
2024 Q3	$1.05M	Buy	+915,509	New	+$1.12M	﹤0.01%	715
2024 Q1	–	Sell	-748,775	Closed	-$786K	–	932
2023 Q4	$786K	Buy	748,775 +573,294	+327%	+$1.75M	﹤0.01%	764
2023 Q3	$1.2M	Buy	175,481 +124,132	+242%	+$1.06M	0.01%	644
2023 Q2	$532K	Sell	51,349 -8,111	-14%	-$73.4K	﹤0.01%	813
2023 Q1	$481K	Buy	+59,460	New	+$755K	﹤0.01%	809
2020 Q1	–	Sell	-111,166	Closed	-$210K	–	994
2019 Q4	$210K	Buy	+111,166	New	+$184K	﹤0.01%	931

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management's ACRS Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 460,842 shares — an estimated $705K sold.

Jacobs Levy Equity Management first reported a position in ACRS in Q4 2019 and held it in 8 quarters. The position peaked at $1.43M in Q4 2024. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

Jacobs Levy Equity Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 460,842 Aclaris Therapeutics shares in Q2 2025, an estimated $705K.
Jacobs Levy Equity Management first reported a position in Aclaris Therapeutics in Q4 2019 and held it in 8 quarters.
Jacobs Levy Equity Management's Aclaris Therapeutics position peaked at $1.43M in Q4 2024.
96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.